文献速递创面修复

整形外科住院患者每日两次依诺肝素:药效学、90天静脉血栓栓塞及90天出血的考察

Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
PubMed 文献 · Plast Reconstr Surg · 2018-01-01

118例整形与重建术后成人住院患者接受依诺肝素40 mg每日两次,9.6%峰值抗Xa因子水平低(<0.2 IU/ml)、62.6%在目标范围(0.2–0.4 IU/ml)、27.8%偏高(>0.4 IU/ml),90.4%达到至少充分预防。90天症状性静脉血栓栓塞为0例,临床相关出血8例(6.8%)。

要点

  • 依诺肝素40 mg每日两次时90.4%患者达到至少充分预防(抗Xa因子>0.2 IU/ml)。
  • 27.8%患者抗Xa因子>0.4 IU/ml,属过度治疗。
  • 90天急性静脉血栓栓塞0例,临床相关出血6.8%(8例)。

核心结论

  • 依诺肝素40 mg每日两次时90%患者获得至少充分的静脉血栓栓塞预防(抗Xa因子>0.2 IU/ml),但总体人群中27%被过度治疗(抗Xa因子>0.4 IU/ml)。
  • 这些药效学数据可能解释观察到的低90天急性静脉血栓栓塞率(0%)和高临床相关出血率(6.8%)。
  • 需要未来研究以更好地优化整形与重建外科患者依诺肝素预防的风险与获益。

研究设计与样本

  • 成人患者于整形与重建手术后入院并接受依诺肝素40 mg每日两次。
  • 共纳入118例患者,采血测定峰值抗Xa因子水平,目标水平为0.2至0.4 IU/ml。
  • 识别90天症状性静脉血栓栓塞与临床相关出血。
  • 证据级别:治疗性,IV级。

主要发现

  • 9.6%患者峰值抗Xa因子水平低(<0.2 IU/ml)。
  • 62.6%患者峰值抗Xa因子水平在目标范围(0.2至0.4 IU/ml)。
  • 27.8%患者抗Xa因子水平高(>0.4 IU/ml)。
  • 依诺肝素40 mg每日两次时90.4%患者至少获得充分预防。
  • 患者体重预测依诺肝素代谢的快慢;90天急性静脉血栓栓塞为0例;8例(6.8%)发生临床相关90天出血,临床后果从停止依诺肝素预防到输血到手术清除血肿不等。

局限性

  • 需要未来研究以更好地优化整形与重建外科患者依诺肝素预防的风险与获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low anti-factor Xa level, indicative of inadequate enoxaparin dosing, has a significant association with 90-day venous thromboembolism events. The authors examined the pharmacodynamics of enoxaparin 40 mg twice daily and its correlation with anti-factor Xa level, postoperative venous thromboembolism, and bleeding. METHODS: Adult patients were admitted after plastic and reconstructive surgery and received enoxaparin 40 mg twice daily. Peak anti-factor Xa levels, which quantify enoxaparin's antithrombotic effect, were drawn, with a goal level of 0.2 to 0.4 IU/ml. Ninety-day symptomatic venous thromboembolism and clinically relevant bleeding were identified. RESULTS: The authors enrolled 118 patients who received enoxaparin 40 mg twice daily. Of these patients, 9.6 percent had low peak anti-factor Xa levels (<0.2 IU/ml), 62.6 percent had in-range peak anti-factor Xa levels (0.2 to 0.4 IU/ml), and 27.8 percent had high anti-factor Xa levels (>0.4 IU/ml). With enoxaparin 40 mg twice daily, 90.4 percent of patients received at least adequate prophylaxis. Patient weight predicted the rapidity of enoxaparin metabolism. Zero acute 90-day venous thromboembolism occurred. Eight patients (6.8 percent) had clinically relevant 90-day bleeding: clinical consequences ranged from cessation of enoxaparin prophylaxis to transfusion to operative hematoma evacuation. CONCLUSIONS: When enoxaparin 40 mg twice daily is provided, 90 percent of patients receive at least adequate venous thromboembolism prophylaxis (anti-factor Xa level >0.2 IU/ml). However, 27 percent of the overall population is overtreated (anti-factor Xa level >0.4 IU/ml). These pharmacodynamics data likely explain the low rate of 90-day acute venous thromboembolism (0 percent) and the high rate of clinically relevant bleeding (6.8 percent) observed. Future studies are needed to better optimize the risks and benefits of enoxaparin prophylaxis in plastic and reconstructive surgery patients. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Pannucci CJ, Fleming KI, Momeni A, et al. Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding. Plast Reconstr Surg. 2018. PMID: 29608533. doi:10.1097/PRS.0000000000004379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。